PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	itute for form 1449/PTO	7101011	000, 110 00.000.00 010 100,000.00	d to respond to a collection of information unless it contains a valid OMB control number Complete if Known		
Cubor				Application Number	10/599,143	
10.17			SCI ACHDE	Filing Date .		
			SCLOSURE	First Named Inventor	Lain-Yen Hu	
ST	ATEMENT I	BY A	APPLICANT	Art Unit		
	(Use as many sh	eets as	necessary)	Examiner Name		
Sheet	1	of	4	Attorney Docket Number	PC32134A	

			U. S. PATENT D		
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	ļ.,	Number-Kind Code <sup>2 (If known)</sup>			rigures Appear
		US-			,
		US-			
	<del></del>	US-			:
		US-			
		US-			
<del>,</del>		US-			
		US-			
		US-			1
		US-			
	-	US-			
		US-			
	ļ <u>.</u>	US-			

FOREIGN PATENT DOCUMENTS							
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	T	
		WO9510521A1		Abstract			
		WO9735845A1		Abstract			
		WO99/08673A	02-25-1999	Bristol-Myers Squibb			
		WO99/17777	04-15-1999	Merck & Co. Inc.			
		WO2005000794	01-06-2005	Orion Corp.			
	<u> </u>	WO2005013914A	02-17-2005	Vertex Pharm Inc.	•		

	· ,'	
Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/599,143 Filing Date INFORMATION DISCLOSURE First Named Inventor Lain-Yen Hu STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) Examiner Name Attorney Docket Number PC32134A of Sheet

			U.S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2 (# known)</sup>			rigures Appear
		US-			,
		US-			
		US-		1 0 1 1100011000110001	
		US-			
		US			
		US-			
		US-			ì
		US-			
		US-			,
		US-			
		US-			
		US-			1
		US-			
		US-			
		US-		THE	
		US-			

		FORE	IGN PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
		WO02060896A	08-08-2002	Pfizer Products Inc	·	
		WO03/065992A	08-14-2003	GTX Inc.		
						<u> </u>
						<u> </u>
					·	

	• D	
Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Cubatitud	te for form 1449/PTO				Complete if Known
_ อนมธิติเนา	10 101 101111 1449/F 10			Application Number	10/599,143
INF	ORMATIO	N DIS	CLOSURE	Filing Date	
STA	STATEMENT BY APPLICANT			First Named Inventor	Lain-Yen Hu
				Art Unit	
	(Use as many sl	reets as ne	ecessary)	Examiner Name	
Sheet	3	of	4	Attorney Docket Number	PC32134A

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Abstract:: ARNOLD, DONALD R. et al., Radical ions in photochemistry. Part 20. The photochemical nucleophile-olefin combination, aromatic substitution reaction. Canadian Journal of Chemistry (1988) 66 (12), 3012-26.	
		GREGORIO ASENSIO ET AL., Synthesis of an enantiopure 2-arylcyclohexanols form prochiral enol acetates by an enantioselective protonation/diasteroselective reduction sequence, Tetrahedron: Asymmetry 14(2003) 3851-3855.	
		ALEXANDRE ALEXAKIS ET AL., Enantioselective Nucleophilic Opening fo meso Epoxides by Organolithium Reagents, SYNLETT October 1998, pages 1165-1167.	
		SHANKAR M. SHINGH ET AL., Androgen Receptor Antagonists (Antiandrogens): Structure-Activity Relationships, Current Medicinal Chemistry, 2000, 7, 211-247.	
· ·		Derwent English Abstract of German Patent Application (DE3939116A1)	
		Micropatent English Abstract of Japanese Patent (JP2001-247411)	
		BOHL, CASEY E., ET AL, Structural basis for antagonism and resistance of bicalutamide in prostate cancer, PNAS, April 26, 2005, vol. 102, uo. 17 pages 6201-6206.	
		PALUCKI, M. et al., "Palladium-catalyzed intermolecular carbon-oxygen bond formation; A new sysnthesis of aryl ethers" J. Am. Chem. Soc., 1997, Vol. 119, nr. 14, pgs 3395-3396.	
		Related Co Pending United States Application 11/053,010	
		DATABASE CA [Online] Chemical Abstracts Service, Columbus, Ohio, US; YASUDA, KOSUKE et al: "Preparation of aliphatic uitrogenous five-membered ring compounds as dipeptidyl peptidase IV inhibitors" XP002350473 retrived from STN Database accession no. 136:325560	

Examiner	Date	
Signature	Considered	,

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/599,143 INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor Lain-Yen Hu Art Unit (Use as many sheets as necessary) **Examiner Name** Attorney Docket Number 4 PC32134A Sheet αf

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DATABASE CA [Online] Chemical Abstracts Service, Columbus, Ohio, US; CHAKI, HISAAKI ET AL: "Preparation and formulation of alkylsulfonylbiphenyl and aminosulfonylbiphenyl derivatives as selective COX-2 inhibitors" XP002350472 retrieved from STN Database accession no 125:300608	
		PATENT ABSTRACTS OF JAPAN vol. 013, no. 021 (C-560), 18 January 1989 (1989-01-18) & JP 63227502A (SDS BIOTECH KK), 21 September 1988 (1988-09-21)	
		REILING B A ET AL: "Effect of prenatal androgenization on performance, lactation, carcass, and sensory traits of heifers in a single-calf heifer system" JOURNAL OF ANIMAL SCIENCE, vol. 73, no. 4, 1995, pages 986-992, XP0088065209 ISSN: 0021-8812	
		HEITZMAN R J: "The effectiveness of anabolic agents in increasing rate of growth in farm animals; report on experiments in cattle." ENVIRONMENTAL QUALITY AND SAFETY. SUPPLEMENT, 1976, no. 5, 1976, pages 89-98, XP008065222 ISSN: 0340-4714	
		BOTZKI, SALMEN: "Structure based design" COMINATORIAL SCIENCE, vol. 24, no. 4, 2005, pages 458-469, XP008065218	
		LOEFFLER L J ET AL: "Synthesis of Isosteres of P-Amidinophenylpyruvic Acid Inhibitors of Trypsin, Thrombin, and Pancreatic Kallikrein" 1 March 1975 J. Of Med Chem, Amer. Chem. Soc. Wash. Pages 287-292 XP000574801 ISSN: 0022-2623	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.